Abstract
Oesophageal cancer is a global health problem with high mortality due to the advanced nature of the disease at presentation; therefore, detection at an early stage significantly improves outcome. Oesophageal squamous-cell cancer is preceded by dysplasia and oesophageal adenocarcinoma is preceded by Barrett's oesophagus, which progresses to cancer via intermediate dysplastic stages. Screening to detect these preneoplastic lesions has the potential to substantially reduce mortality and morbidity. However, the risks and benefits of such programmes to individuals and to society need to be carefully weighed. Endoscopic screening is invasive, costly and error prone owing to sampling bias and the subjective diagnosis of dysplasia. Non-endoscopic cell-sampling methods are less invasive and more cost effective than endoscopy, but the sensitivity and specificity of cytological assessment of atypia has been disappointing. The use of biomarkers to analyse samples collected using pan-oesophageal cell-collection devices may improve diagnostic accuracy; however, further work is required to confirm this. The psychological and economic implications of screening as well as the feasibility of implementing such programmes must also be considered.
Key Points
-
Oesophageal cancer is a public health concern worldwide
-
With the abysmal outcome for oesophageal cancer (5-year survival <20%) pursuit of a screening strategy is essential
-
Increased public awareness coupled with early diagnosis is likely to have the biggest impact on reducing population mortality from oesophageal cancer
-
Advances in diagnostic technologies and minimally invasive treatments mean that the time is ripe to consider a formalized screening programme for this disease
-
Screening tests should be of low cost and easily administered from the perspective of the patient and the health-care provider
-
Further research in quality of life, economics, biomarkers and device technologies is required to allow screening to be adopted into clinical practice
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rodman, W. L. IV. Cancer and precancerous conditions. Ann. Surg. 59, 47–64 (1914).
Cancer: Early detection of cancer. World Health Organization [online], (2010).
Cancer: Screening for various cancers. World Health Organization [online] (2012).
NHS. NHS Cervical Screening Programme [online], (2012).
Machii, R. & Saito, H. Time trends in cervical cancer screening rates in the OECD countries. Jpn. J. Clin. Oncol. 41, 731–732 (2011).
Benson, V. S. et al. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int. J. Cancer 122, 1357–1367 (2008).
NHS. NHS Bowel Cancer Screening Programme [online], (2011).
Fitzgerald, R. C. (Ed.) Pre-invasive disease: pathogenesis and clinical management 1st edn (Springer, London, 2011).
Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010).
Day, N. E. Some aspects of the epidemiology of esophageal cancer. Cancer Res. 35, 3304–3307 (1975).
Wu, M. et al. A large proportion of esophageal cancer cases and the incidence difference between regions are attributable to lifestyle risk factors in China. Cancer Lett. 308, 189–196 (2011).
Nasrollahzadeh, D. et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br. J. Cancer 98, 1857–1863 (2008).
Kamangar, F., Chow, W. H., Abnet, C. C. & Dawsey, S. M. Environmental causes of esophageal cancer. Gastroenterol. Clin. North Am. 38, 27–57 (2009).
Lepage, C., Rachet, B., Jooste, V., Faivre, J. & Coleman, M. P. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am. J. Gastroenterol. 103, 2694–2699 (2008).
Pohl, H., Sirovich, B. & Welch, H. G. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol. Biomarkers Prev. 19, 1468–1470 (2010).
Steevens, J., Botterweck, A. A., Dirx, M. J., van den Brandt, P. A. & Schouten, L. J. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur. J. Gastroenterol. Hepatol. 22, 669–678 (2010).
Bosetti, C. et al. Trends in oesophageal cancer incidence and mortality in Europe. Int. J. Cancer 122, 1118–1129 (2008).
Devesa, S. S., Blot, W. J. & Fraumeni, J. F. Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83, 2049–2053 (1998).
Lagergren, J. Oesophageal cancer and gastro-oesophageal reflux: what is the relationship? Gut 53, 1064–1065 (2004).
Rubenstein, J. H., Scheiman, J. M., Sadeghi, S., Whiteman, D. & Inadomi, J. M. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am. J. Gastroenterol. 106, 254–260 (2011).
Li, J. et al. Major cancer mortality and changes in Yanting, 2004–2009: introduction to cancer challenges in a high risk area. Asian Pac. J. Cancer Prev. 12, 409–413 (2011).
Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359, 1727–1733 (2002).
Aghcheli, K. et al. Prognostic factors for esophageal squamous cell carcinoma—a population-based study in Golestan Province, Iran, a high incidence area. PLoS One 6, e22152 (2011).
Prasad, G. A. et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 137, 815–823 (2009).
Wang, G. Q. et al. Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening. Ann. Thorac. Surg. 77, 1740–1744 (2004).
Rex, D. K. et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125, 1670–1677 (2003).
Gerson, L. B. & Banerjee, S. Screening for Barrett's esophagus in asymptomatic women. Gastrointest. Endosc. 70, 867–873 (2009).
Wilson, J. M. G. & Jungner, G. Principles and practice of screening for disease. WHO [online], (1968).
Wang, G. Q. et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut 54, 187–192 (2005).
Sikkema, M., de Jonge, P. J., Steyerberg, E. W. & Kuipers, E. J. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 8, 235–244 (2010).
Yousef, F. et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am. J. Epidemiol. 168, 237–249 (2008).
Hvid-Jensen, F., Pedersen, L., Drewes, A. M., Sorensen, H. T. & Funch-Jensen, P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 365, 1375–1383 (2011).
Desai, T. K. et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut (in press).
National Oesophago-Gastric Cancer Audit. RCS advancing surgical standards [online], (2010).
Rees, J. R., Lao-Sirieix, P., Wong, A. & Fitzgerald, R. C. Treatment for Barrett's oesophagus. Cochrane Database Syst. Rev. 1, CD004060 (2010).
Shaheen, N. J. et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N. Engl. J. Med. 360, 2277–2288 (2009).
Shaheen, N. J. et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 141, 460–468 (2011).
Brouwers, M. C. et al. Effective interventions to facilitate the uptake of breast, cervical and colorectal cancer screening: an implementation guideline. Implement Sci. 6, 112 (2011).
Brouwers, M. C. et al. What implementation interventions increase cancer screening rates? A systematic review. Implement Sci. 6, 111 (2011).
Fitzgerald, R. C. in Oxford Textbook of Medicine 5th edn Vol. 2 Ch. 15.7 (ed. Warrell, D. A., Cox, T. M. & John, J. D.) 2286–2304 (Oxford University Press, Oxford, 2010).
Dawsey, S. M. et al. Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. Cancer 83, 220–231 (1998).
Wang, G. Q. et al. Significance of screening by iodine staining of endoscopic examination in the area of high incidence of esophageal carcinoma [Chinese]. Ai Zheng 22, 175–177 (2003).
Dong Wang, L. et al. Endoscopic screening and determination of p53 and proliferating cell nuclear antigen in esophageal multistage carcinogenesis: a comparative study between high- and low-risk populations in Henan, northern China. Dis. Esophagus 15, 80–84 (2002).
Yang, H. et al. Cytologic screening for esophageal cancer in a high-risk population in Anyang County, China. Acta Cytol. 46, 445–452 (2002).
Bergman, J. J. et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. Gastrointest. Endosc. 74, 1181–1190 (2011).
Ronkainen, J. et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129, 1825–1831 (2005).
Kadri, S. R. et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 341, c4372 (2010).
Reid, B. J. et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 94, 81–90 (1988).
American Gastroenterological Association et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140, 1084–1091 (2011).
Canto, M. I. & Kalloo, A. Chromoendoscopy for Barrett's esophagus in the twenty-first century: to stain or not to stain? Gastrointest. Endosc. 64, 200–205 (2006).
Curvers, W. L. et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology 139, 1106–1114 (2010).
Bird-Lieberman, E. L. et al. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat. Med. 18, 315–321 (2012).
Li, M. et al. Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology 139, 1472–1480 (2010).
Thota, P. N. et al. A randomized prospective trial comparing unsedated esophagoscopy via transnasal and transoral routes using a 4-mm video endoscope with conventional endoscopy with sedation. Endoscopy 37, 559–565 (2005).
Catanzaro, A. et al. Prospective evaluation of 4-mm diameter endoscopes for esophagoscopy in sedated and unsedated patients. Gastrointest. Endosc. 57, 300–304 (2003).
Faulx, A. L. et al. Patient tolerance and acceptance of unsedated ultrathin esophagoscopy. Gastrointest. Endosc. 55, 620–623 (2002).
Shariff, M. K. et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. Gastrointest. Endosc. (in press).
Jobe, B. A. et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison. Am. J. Gastroenterol. 101, 2693–2703 (2006).
Saeian, K. et al. Unsedated transnasal endoscopy accurately detects Barrett's metaplasia and dysplasia. Gastrointest. Endosc. 56, 472–478 (2002).
Ramirez, F. C., Akins, R. & Shaukat, M. Screening of Barrett's esophagus with string-capsule endoscopy: a prospective blinded study of 100 consecutive patients using histology as the criterion standard. Gastrointest. Endosc. 68, 25–31 (2008).
Mylonaki, M., Fritscher-Ravens, A. & Swain, P. Wireless capsule endoscopy: a comparison with push enteroscopy in patients with gastroscopy and colonoscopy negative gastrointestinal bleeding. Gut 52, 1122–1126 (2003).
Pan, Q. J. et al. Cytologic detection of esophageal squamous cell carcinoma and its precursor lesions using balloon samplers and liquid-based cytology in asymptomatic adults in Llinxian, China. Acta Cytol. 52, 14–23 (2008).
Roth, M. J. et al. Cytologic detection of esophageal squamous cell carcinoma and precursor lesions using balloon and sponge samplers in asymptomatic adults in Linxian, China. Cancer 80, 2047–2059 (1997).
Falk, G. W. et al. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology 112, 1787–1797 (1997).
Qin, D. X. et al. Screening of esophageal and gastric cancer by occult blood bead detector. Cancer 71, 216–218 (1993).
Hu, N. et al. Quantitative fluorescence image analysis of DNA content and nuclear morphology on esophageal balloon cytology smears and subsequent development of esophageal and gastric cardia cancer in Linxian, China. Cancer Epidemiol. Biomarkers Prev. 7, 59–64 (1998).
Triadifilopoulos, G. Cytosponge for Barrett's esophagus screening: when smart science matches simplicity. Gastroenterology 141, 766–768 (2011).
Lao-Sirieix, P. et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 58, 1451–1459 (2009).
Weller, D. et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br. J. Cancer 97, 1601–1605 (2007).
Mistry, K. & Cable, G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J. Am. Board Fam. Pract. 16, 95–101 (2003).
Ferrini, R., Mannino, E., Ramsdell, E. & Hill, L. Screening mammography for breast cancer: American College of Preventive Medicine practice policy statement. Am. J. Prev. Med. 12, 340–341 (1996).
Bhat, S. et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J. Natl Cancer Inst. 103, 1049–1057 (2011).
BEST2. CPTU Cancer Prevention Trials Unit [online], (2011).
Abnet, C. C. et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat. Genet. 42, 764–767 (2010).
von Brevern, M. et al. Loss of heterozygosity in sporadic oesophageal tumors in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q. Oncogene 17, 2101–2105 (1998).
Kelsell, D. P. et al. Close mapping of the focal non-epidermolytic palmoplantar keratoderma (PPK) locus associated with oesophageal cancer (TOC). Hum. Mol. Genet. 5, 857–860 (1996).
Yokoyama, A. et al. Successful screening for early esophageal cancer in alcoholics using endoscopy and mucosa iodine staining. Cancer 76, 928–934 (1995).
Yokoyama, A. et al. Cancer screening of upper aerodigestive tract in Japanese alcoholics with reference to drinking and smoking habits and aldehyde dehydrogenase-2 genotype. Int. J. Cancer 68, 313–316 (1996).
Ban, S., Toyonaga, A., Harada, H., Ikejiri, N. & Tanikawa, K. Iodine staining for early endoscopic detection of esophageal cancer in alcoholics. Endoscopy 30, 253–257 (1998).
Shiozaki, H. et al. Endoscopic screening of early esophageal cancer with the Lugol dye method in patients with head and neck cancers. Cancer 66, 2068–2071 (1990).
Lee, C. T. et al. Narrow-band imaging with magnifying endoscopy for the screening of esophageal cancer in patients with primary head and neck cancers. Endoscopy 42, 613–619 (2010).
Petit, T. et al. Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma. Ann. Oncol. 12, 643–646 (2001).
Morimoto, M. et al. Significance of endoscopic screening and endoscopic resection for esophageal cancer in patients with hypopharyngeal cancer. Jpn J. Clin. Oncol. 40, 938–943 (2010).
Makuuchi, H. et al. Endoscopic screening for esophageal cancer in 788 patients with head and neck cancers. Tokai J. Exp. Clin. Med. 21, 139–145 (1996).
Murakami, S. et al. The utility of endoscopic screening for patients with esophageal or head and neck cancer. Dis. Esophagus 12, 186–190 (1999).
Gerson, L. B., Edson, R., Lavori, P. W. & Triadafilopoulos, G. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am. J. Gastroenterol. 96, 2005–2012 (2001).
Rubenstein, J. H. & Taylor, J. B. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment. Pharmacol. Ther. 32, 1222–1227 (2010).
Fass, R. & Dickman, R. Clinical consequences of silent gastroesophageal reflux disease. Curr. Gastroenterol. Rep. 8, 195–201 (2006).
Shaheen, N. J. Editorial: should women with heartburn undergo screening upper endoscopy for prevention of cancer? Am. J. Gastroenterol. 106, 261–263 (2011).
Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M. & Shaheen, N. J. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140, 1084–1091 (2011).
Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M. & Shaheen, N. J. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 140, e18–e52 (2011).
Edelstein, Z. R., Bronner, M. P., Rosen, S. N. & Vaughan, T. L. Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am. J. Gastroenterol. 104, 834–842 (2009).
Thota, P. N. et al. A randomized prospective trial comparing unsedated esophagoscopy via transnasal and transoral routes using a 4-mm video endoscope with conventional endoscopy with sedation. Endoscopy 37, 559–565 (2005).
Faulx, A. L. et al. Patient tolerance and acceptance of unsedated ultrathin esophagoscopy. Gastrointest. Endosc. 55, 620–623 (2002).
Whistance, R. N., Potter, S., Eveleigh, M. & Blazeby, J. M. in Pre-invasive disease: pathogenesis and clinical management 1st edn Ch. 13 (ed. Fitzgerald, R. C.) 245–268 (Springer, London, 2011).
Barbiere, J. M. & Lyratzopoulos, G. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review. Gastroenterology 137, 1869–1876 (2009).
Corley, D. A., Kerlikowske, K., Verma, R. & Buffler, P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 124, 47–56 (2003).
Rothwell, P. M. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377, 31–41 (2011).
Flossmann, E. & Rothwell, P. M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369, 1603–1613 (2007).
Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741–1750 (2010).
Cook, N. R. et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294, 47–55 (2005).
Das, D., Chilton, A. P. & Jankowski, J. A. Chemoprevention of oesophageal cancer and the ASPECT trial. Recent Results Cancer Res. 181, 161–169 (2009).
Stoner, G. D., Wang, L. S. & Chen, T. Chemoprevention of esophageal squamous cell carcinoma. Toxicol. Appl. Pharmacol. 224, 337–349 (2007).
Limburg, P. J. et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 129, 863–873 (2005).
Bul, M. & Schroder, F. H. Screening for prostate cancer—the controversy continues, but can it be resolved? Acta Oncol. 50 (Suppl. 1), 4–11 (2011).
Weeks, B. E., Friedenberg, L. M., Southwell, B. G. & Slater, J. S. Behavioral consequences of conflict-oriented health news coverage: the 2009 mammography guideline controversy and online information seeking. Health Commun. 27, 158–166 (2012).
Cusumano, P. G. & Lifrange, E. The cancer screening controversy. Eur. J. Cancer Prev. 20 (Suppl. 1), 1 (2011).
Lin, O. S. et al. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett's esophagus in patients with chronic gastroesophageal reflux. Gastrointest. Endosc. 65, 577–583 (2007).
Galmiche, J. P. et al. Screening for esophagitis and Barrett's esophagus with wireless esophageal capsule endoscopy: a multicenter prospective trial in patients with reflux symptoms. Am. J. Gastroenterol. 103, 538–545 (2008).
Wang, G., Zhou, M. & Cong, Q. Lugol's solution in endoscopic diagnosis of early esophageal cancer [Chinese]. Zhonghua Yi Xue Za Zhi 75, 417–418 (1995).
Wang, G. Q. et al. Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening. Ann. Thorac. Surg. 77, 1740–1744 (2004).
Wang, L. D. et al. Cytological screening and 15 years' follow-up (1986–2001) for early esophageal squamous cell carcinoma and precancerous lesions in a high-risk population in Anyang County, Henan Province, Northern China. Cancer Detect. Prev. 29, 317–322 (2005).
Lazarus, C., Jaskiewicz, K., Sumeruk, R. A. & Nainkin, J. Brush cytology technique in the detection of oesophageal carcinoma in the asymptomatic, high risk subject; a pilot survey. Cytopathology 3, 291–296 (1992).
Li, F. P. & Shiang, E. L. Screening for oesophageal cancer in 62,000 Chinese. Lancet 2, 804 (1979).
Shen, O. et al. Cytologic screening for esophageal cancer: results from 12,877 subjects from a high-risk population in China. Int. J. Cancer 54, 185–188 (1993).
Author information
Authors and Affiliations
Contributions
Both authors researched the data for the article, provided substantial contributions to discussions of its content, wrote the article and undertook review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare grant or research support and patents held with the Medical Research Council (Cell sampling device patent n# PCT/GB2010/002077; Biomarker for Barrett's oesophagus patent n# 12/833,548) and grant support from Cancer Research UK.
Rights and permissions
About this article
Cite this article
Lao-Sirieix, P., Fitzgerald, R. Screening for oesophageal cancer. Nat Rev Clin Oncol 9, 278–287 (2012). https://doi.org/10.1038/nrclinonc.2012.35
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.35
This article is cited by
-
Construction and external validation of a nomogram model for predicting the risk of esophageal stricture after endoscopic submucosal dissection: a multicenter case–control study
BMC Gastroenterology (2023)
-
Non-endoscopic Screening for Esophageal Squamous Cell Carcinoma: Recent Advances
Journal of Gastrointestinal Cancer (2023)
-
Targeted demethylation at ZNF154 promotor upregulates ZNF154 expression and inhibits the proliferation and migration of Esophageal Squamous Carcinoma cells
Oncogene (2022)
-
Suprabasin: Role in human cancers and other diseases
Molecular Biology Reports (2022)
-
International trends in esophageal cancer incidence rates by histological subtype (1990–2012) and prediction of the rates to 2030
Esophagus (2022)